Antibacterial treatment strategies in hospitalized patients: What role for pharmacoeconomics?

Article Type
Changed
Tue, 09/25/2018 - 14:59
Display Headline
Antibacterial treatment strategies in hospitalized patients: What role for pharmacoeconomics?
Article PDF
Author and Disclosure Information

Morton P. Goldman, PharmD, BCPS
Director, Pharmacotherapy Services, Department of Pharmacy, Cleveland Clinic, Cleveland, OH

Radhika Nair, PhD
Health Sciences Researcher, Abbott Laboratories, Austin, TX*

Correspondence: Morton P. Goldman, PharmD, BCPS, Department of Pharmacy, QQb5, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; goldmam@ccf.org

*At the time this article was written, Dr. Nair was Outcomes Research Specialist, Department of Pharmacy, Cleveland Clinic, Cleveland, OH.

Dr. Goldman reported that he has received fees for serving on speakers’ bureaus for Enzon Pharmaceuticals, Wyeth Pharmaceuticals, Abbott Laboratories, Schering-Plough Corp., Forest Laboratories, and Pfizer Inc., and that he has received honoraria for writing from Wyeth.

Dr. Nair reported that she receives a salary from Abbott Laboratories (her current employer) and that she has received honoraria for writing from Wyeth.

The authors reported that they prepared this article without assistance from any medical education company.

Publications
Page Number
S38-S47
Author and Disclosure Information

Morton P. Goldman, PharmD, BCPS
Director, Pharmacotherapy Services, Department of Pharmacy, Cleveland Clinic, Cleveland, OH

Radhika Nair, PhD
Health Sciences Researcher, Abbott Laboratories, Austin, TX*

Correspondence: Morton P. Goldman, PharmD, BCPS, Department of Pharmacy, QQb5, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; goldmam@ccf.org

*At the time this article was written, Dr. Nair was Outcomes Research Specialist, Department of Pharmacy, Cleveland Clinic, Cleveland, OH.

Dr. Goldman reported that he has received fees for serving on speakers’ bureaus for Enzon Pharmaceuticals, Wyeth Pharmaceuticals, Abbott Laboratories, Schering-Plough Corp., Forest Laboratories, and Pfizer Inc., and that he has received honoraria for writing from Wyeth.

Dr. Nair reported that she receives a salary from Abbott Laboratories (her current employer) and that she has received honoraria for writing from Wyeth.

The authors reported that they prepared this article without assistance from any medical education company.

Author and Disclosure Information

Morton P. Goldman, PharmD, BCPS
Director, Pharmacotherapy Services, Department of Pharmacy, Cleveland Clinic, Cleveland, OH

Radhika Nair, PhD
Health Sciences Researcher, Abbott Laboratories, Austin, TX*

Correspondence: Morton P. Goldman, PharmD, BCPS, Department of Pharmacy, QQb5, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; goldmam@ccf.org

*At the time this article was written, Dr. Nair was Outcomes Research Specialist, Department of Pharmacy, Cleveland Clinic, Cleveland, OH.

Dr. Goldman reported that he has received fees for serving on speakers’ bureaus for Enzon Pharmaceuticals, Wyeth Pharmaceuticals, Abbott Laboratories, Schering-Plough Corp., Forest Laboratories, and Pfizer Inc., and that he has received honoraria for writing from Wyeth.

Dr. Nair reported that she receives a salary from Abbott Laboratories (her current employer) and that she has received honoraria for writing from Wyeth.

The authors reported that they prepared this article without assistance from any medical education company.

Article PDF
Article PDF
Related Articles
Page Number
S38-S47
Page Number
S38-S47
Publications
Publications
Article Type
Display Headline
Antibacterial treatment strategies in hospitalized patients: What role for pharmacoeconomics?
Display Headline
Antibacterial treatment strategies in hospitalized patients: What role for pharmacoeconomics?
Citation Override
Cleveland Clinic Journal of Medicine 2007 August;74(suppl 4):S38-S47
PURLs Copyright

Disallow All Ads
Alternative CME
Use ProPublica
Article PDF Media

Antiviral agents for treating influenza

Article Type
Changed
Mon, 02/04/2019 - 10:18
Display Headline
Antiviral agents for treating influenza
Article PDF
Author and Disclosure Information

Jennifer K. Long, PharmD
Department of Pharmacy, Cleveland Clinic

Sherif B. Mossad, MD
Department of Infectious Diseases, Cleveland Clinic

Morton P. Goldman, PharmD
Department of Pharmacy, Cleveland Clinic

Dr. Mossad serves on the speakers' bureau of Roche Pharmaceuticals (which makes oseltamivir).

Dr. Goldman serves on the speakers' bureau of Roche Pharmaceuticals and Glaxo Wellcome Inc. (which makes zanamivir).

Issue
Cleveland Clinic Journal of Medicine - 67(2)
Publications
Topics
Page Number
92-95
Sections
Author and Disclosure Information

Jennifer K. Long, PharmD
Department of Pharmacy, Cleveland Clinic

Sherif B. Mossad, MD
Department of Infectious Diseases, Cleveland Clinic

Morton P. Goldman, PharmD
Department of Pharmacy, Cleveland Clinic

Dr. Mossad serves on the speakers' bureau of Roche Pharmaceuticals (which makes oseltamivir).

Dr. Goldman serves on the speakers' bureau of Roche Pharmaceuticals and Glaxo Wellcome Inc. (which makes zanamivir).

Author and Disclosure Information

Jennifer K. Long, PharmD
Department of Pharmacy, Cleveland Clinic

Sherif B. Mossad, MD
Department of Infectious Diseases, Cleveland Clinic

Morton P. Goldman, PharmD
Department of Pharmacy, Cleveland Clinic

Dr. Mossad serves on the speakers' bureau of Roche Pharmaceuticals (which makes oseltamivir).

Dr. Goldman serves on the speakers' bureau of Roche Pharmaceuticals and Glaxo Wellcome Inc. (which makes zanamivir).

Article PDF
Article PDF
Issue
Cleveland Clinic Journal of Medicine - 67(2)
Issue
Cleveland Clinic Journal of Medicine - 67(2)
Page Number
92-95
Page Number
92-95
Publications
Publications
Topics
Article Type
Display Headline
Antiviral agents for treating influenza
Display Headline
Antiviral agents for treating influenza
Sections
PURLs Copyright

Disallow All Ads
Alternative CME
Use ProPublica
Article PDF Media